AZD5991 + venetoclax

AZD5991 + venetoclax is an investigational combination therapy for hematologic malignancies, particularly relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). AZD5991 is a potent, selective small molecule inhibitor of the anti-apoptotic protein Mcl-1, a member of the Bcl-2 family that promotes tumor cell survival. By directly binding to Mcl-1, AZD5991 induces apoptosis in cancer cells overexpressing this protein. Venetoclax is an approved small molecule inhibitor of BCL-2, another anti-apoptotic protein in the same family. The combination aims to enhance pro-apoptotic signaling by simultaneously inhibiting both Mcl-1 and BCL-2 pathways. Preclinical studies have shown synergistic antitumor activity with this combination in models of AML and multiple myeloma. Clinical trials are ongoing to assess safety and efficacy in patients with relapsed or refractory hematologic malignancies[2][3][4][5][8].

Other names

AZD-5991AZD5991AZD 5991ABT-199 (for venetoclax)